Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When a single RNAi therapy can pivot on a line item buried deep in the footnotes, Arrowhead Pharmaceuticals’ SEC documents often feel like a molecular biology textbook. R&D expenses for the TRIM™ delivery platform, milestone payments from licensing partners, and trial safety data are scattered across hundreds of pages. If you have ever asked, “How do I find Arrowhead Pharmaceuticals insider trading Form 4 transactions?” you already know the challenge.
Stock Titan solves it. Our AI reads every Arrowhead Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR, highlights fresh cash-burn metrics, and flags clinical milestone language. It pulls executive stock sales from Arrowhead Pharmaceuticals Form 4 insider transactions real-time, summarizes 8-K material events explained in plain English, and converts the 300-page annual report into an Arrowhead Pharmaceuticals annual report 10-K simplified digest. You also get quick answers to natural questions like “understanding Arrowhead Pharmaceuticals SEC documents with AI” or “Arrowhead Pharmaceuticals proxy statement executive compensation.”
Here’s what you can do in one dashboard:
- Track Arrowhead Pharmaceuticals executive stock transactions Form 4 alongside pipeline catalysts
- Compare R&D spend across periods with Arrowhead Pharmaceuticals earnings report filing analysis
- Receive instant alerts for every Arrowhead Pharmaceuticals 8-K material event
Stop combing through PDFs. Stock Titan’s expert analysis turns Arrowhead Pharmaceuticals SEC filings explained simply into actionable insight—so you can focus on whether the next gene-silencing breakthrough just moved closer to market.
Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.
Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company’s outstanding stock, indicating minimal dilution risk.
The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:
- 09 Jul 2025 – 200 shares – $602.00
- 22 May 2025 – 1,179 shares – $2,458.33
- 21 May 2025 – 600 shares – $1,262.52
- 20 May 2025 – 800 shares – $1,736.72
- 19 May 2025 – 1,000 shares – $2,226.60
- 16 May 2025 – 1,421 shares – $3,326.13
Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
What is the primary focus of Arrowhead Pharmaceuticals?
How does the TRIM™ platform contribute to the company’s approach?
Which therapeutic areas does Arrowhead address?
What differentiates Arrowhead Pharmaceuticals from other biotechnology companies?
How does RNA interference (RNAi) work in Arrowhead’s therapies?
What challenges might Arrowhead Pharmaceuticals face in its market segment?
How does the company generate revenue without relying on traditional sales?
How does Arrowhead ensure the precision of its gene silencing technology?
